BRAF and neoplasm: A 66-year-old man with rectosigmoid junction CRC initially showed RAS/BRAF wild-type status, microsatellite stability (MSS), and a moderate tumor mutational burden (TMB: 7.1 mutations/Mb) on the primary tumor.